Dual-Receptor GH Stimulation for Pulsatile Growth Hormone Research
CJC-1295 / Ipamorelin Blend — Synergistic GH Secretagogue Combination
Last reviewed: August 2026
The CJC-1295/Ipamorelin blend combines two growth hormone-stimulating peptides that work through different receptors, producing synergistic GH release that closely mimics the body's natural pulsatile GH secretion.
CJC-1295 tells the pituitary to release GH through the GHRH receptor pathway, while Ipamorelin does the same through the ghrelin receptor (GHSR-1a). Using both together produces significantly more GH release than either peptide alone, without cortisol or prolactin elevation.
Growth hormone declines with age, contributing to reduced muscle mass, increased fat, and slower recovery. The CJC-1295/Ipamorelin combination restores youthful GH pulsatility without exogenous GH administration, preserving natural feedback mechanisms.
The CJC-1295/Ipamorelin blend is the gold standard GH secretagogue combination — synergistic dual-receptor activation, pulsatile GH release, and selective action without cortisol or prolactin elevation.
The CJC-1295 / Ipamorelin blend combines two complementary growth hormone secretagogues in a single formulation. CJC-1295 (a GHRH analogue) stimulates the pituitary to release GH through the GHRH receptor, while Ipamorelin (a ghrelin mimetic) activates GH release through the GHSR-1a receptor. Together, they produce synergistic, pulsatile GH release that closely mimics the body's natural GH secretion pattern.
The blend contains equal parts CJC-1295 (a 30-amino-acid GHRH analogue with DAC technology for extended half-life) and Ipamorelin (a 5-amino-acid selective GHSR-1a agonist). The 1:1 ratio is designed to maximize synergistic GH release through complementary receptor pathways.
The CJC-1295/Ipamorelin blend produces synergistic GH release by simultaneously activating GHRH receptors and ghrelin receptors, generating pulses far greater than either peptide alone.
CJC-1295 activates GHRH receptors on somatotroph cells in the anterior pituitary, stimulating GH synthesis and release. Ipamorelin simultaneously activates GHSR-1a (ghrelin receptor) on the same cells, providing a complementary and synergistic signal. The combination produces GH release significantly greater than either peptide alone, while preserving the natural pulsatile pattern.
CJC-1295 activates GHRH receptors while Ipamorelin activates GHSR-1a receptors, producing synergistic GH release significantly greater than either peptide alone.
The combination preserves the natural pulsatile pattern of GH release, maintaining GH receptor sensitivity and avoiding tachyphylaxis.
Unlike older GH secretagogues, Ipamorelin does not stimulate cortisol or prolactin release, making the blend highly selective for GH secretion.
Each outcome rated by the highest level of evidence available. Tiers follow our 5-tier methodology.
Study counts reflect peer-reviewed publications in the evidence database below. "Theoretical" outcomes have mechanistic rationale only. Learn about our evidence tiers →
Peer-reviewed literature supporting the research profile of CJC-1295 / Ipamorelin Blend
The following peer-reviewed studies form the primary evidence base for CJC-1295 / Ipamorelin Blend's research profile. All references are sourced from PubMed, NCBI, and peer-reviewed scientific journals. Published research is available through PubMed, NCBI, and peer-reviewed biomedical journals.
Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006.PMID: 16352683
CJC-1295 component: sustained GH and IGF-1 elevation for up to 6 days after single injection.
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998.PMID: 9849822
Ipamorelin component: selective GH release without cortisol or prolactin elevation.
Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology & Metabolism. 1998.PMID: 9467542
GHS receptor agonism (shared with ipamorelin) increases fat-free mass and energy expenditure.
Blends Research
Purgo Labs list price, read 12 Sep 2026 · per-lot COA on the vendor page
10mg $69.99 → $55.99 with code HEALTH (20% off; price read 1 Nov 2026)
Fast FedEx shipping · Discreet packaging
View full legal status guide →
Source CJC-1295 / Ipamorelin Blend at Purgo Labs
10mg $69.99 list · $55.99 with code HEALTH · lab-verifiable COA per lot
Blend — no study of the combination; CJC-1295 has one small human pharmacology study, ipamorelin has animal data only
The blend pairs a GHRH analogue (CJC-1295, without DAC) with a ghrelin-receptor agonist (ipamorelin). Nobody has studied the two together. CJC-1295's only human data are a small pharmacokinetic study; ipamorelin has never been through a human trial. What can be said comes from those sources and from the known effects of raising growth hormone.
Research-use information only. Research-grade CJC-1295 / Ipamorelin Blend is not an approved medicine; where trial or label figures appear below they belong to the pharmaceutical product studied, not to any research vial. This section does not give dosing or medical advice.
Every rate carries its source. Where no source exists, no rate is printed.
| Effect | Rate (sourced) | Detail | Source |
|---|---|---|---|
| CJC-1295 (component): headache, flushing, injection-site reactions | not quantified | Reported as transient and mild in the healthy-volunteer pharmacology study; no serious adverse events attributed to the drug. | Teichman et al. 2006 (n = ~50, single and multiple doses) |
| Ipamorelin (component) | not quantified | No human adverse-effect data; described as selective for GH release without cortisol/ACTH rise in animal work. | Raun et al. 1998 |
| Effects of raised GH / IGF-1 | not quantified | Water retention, joint aches and altered glucose handling are the known consequences of elevated GH exposure in general; not measured for this blend. | General GH pharmacology |
No study has evaluated this combination. The evidence lives with the components:
Regulatory status: Neither component is approved anywhere. Ipamorelin's development was discontinued; CJC-1295 development stopped after 2006.
Everything above describes CJC-1295 / Ipamorelin Blend the molecule. The risk specific to a research vial is different: it may not contain CJC-1295 / Ipamorelin Blend at the labelled amount, and it may contain what the synthesis left behind. Identity (mass spectrometry), purity (HPLC), measured net content and an endotoxin result are the four lines on a certificate that bear on adverse effects, and only a certificate you can check at the laboratory tells you any of them. This is what we have verified for CJC-1295 / Ipamorelin Blend so far.
22 of the 105 vendors on our scoreboard list CJC-1295 / Ipamorelin Blend with a price we read on the product page (23 Sep 2026–1 Nov 2026). Of those, 21 name their testing laboratory, 18 publish certificates that resolve on the lab's own site, and 20 publish measured milligrams against the label. The full ranking, with every dated price, is on Best CJC-1295 / Ipamorelin Blend Vendors.
| Vendor | Rubric | Lab named | Price read |
|---|---|---|---|
| MyPurePeptidepartner | 10/10 | Janoshik Analytical | $45.00 · 10mg · 1 Nov 2026 |
| Oneday Compoundspartner | 10/10 | ILS Laboratories (San Diego, CA) | $37.79 · 10mg · 29 Oct 2026 |
| Panda Peptides | 10/10 | Janoshik Analytical · ILS Labs (per batch) | $39.99 · 10mg · 25 Oct 2026 |
| Peptide Giantspartner | 10/10 | Janoshik Analytical · Vanguard Laboratory | $47.00 · 10mg · 23 Sep 2026 |
| Purgo Labspartner | 10/10 | SteriGenix · Freedom Diagnostics | $69.99 · 10mg · 1 Nov 2026 |
Top 5 by rubric score; 17 more on the ranking page.
None yet for CJC-1295 / Ipamorelin Blend specifically. The COA library holds the certificates we have read for each vendor on other compounds, which is the next best signal of how that vendor documents a lot.
No study has looked. CJC-1295 on its own caused transient headache, flushing and injection-site reactions in a small healthy-volunteer study; ipamorelin has no human data at all. Beyond that, the honest answer is the general profile of raising growth hormone — fluid retention, joint aches, glucose effects — none of it measured for this blend.
Side-effect section last reviewed 2026-09-13. Moved from the standalone side-effects page on 10 October 2026; text unchanged.
The CJC-1295/Ipamorelin blend is legal to purchase and possess in the United States as a research chemical. Neither CJC-1295 nor Ipamorelin is a controlled substance under the DEA Controlled Substances Act, and neither is FDA-approved for human use.
| Jurisdiction | Status as stated |
|---|---|
| United States | Neither component is a controlled substance. Legal to purchase as a research chemical blend. Not FDA-approved for human use. |
| Canada | Not scheduled substances. Legal for research purposes. Not approved by Health Canada for human use. |
| United Kingdom | Not controlled drugs under the Misuse of Drugs Act. Legal for research purposes. |
| Australia | Not listed as scheduled substances by the TGA. Legal for research purposes. |
| European Union | Not controlled substances in most EU member states. Legal for research purposes. |
| WADA / Sports | Both CJC-1295 and Ipamorelin are prohibited by WADA under S2 (Peptide Hormones, Growth Factors, Related Substances). Athletes subject to drug testing must not use this blend. |
Statements above are as our legal-status page for CJC-1295/Ipamorelin Blend stated them in 2025; they were moved here on 10 October 2026 and were not re-verified in the move. Regulations change. This is general information, not legal advice; check the current position with your own jurisdiction's regulator before relying on it.
No. Neither CJC-1295 nor Ipamorelin is listed as a controlled substance under the US DEA Controlled Substances Act. The blend is not scheduled at the federal level.
Yes. The blend can be legally purchased as a research chemical in the United States. It should not be sold or purchased for human consumption.
No. Neither CJC-1295 nor Ipamorelin is FDA-approved for human use. They are studied as research chemicals for growth hormone secretagogue research.
Yes. Both CJC-1295 and Ipamorelin are prohibited by WADA under S2 (Peptide Hormones, Growth Factors). Athletes subject to anti-doping rules must not use this blend.
Neither component is listed as a scheduled substance by the TGA in Australia. However, regulations can change — always verify current status before purchasing.
CJC-1295/Ipamorelin blend is a commonly used research combination. No clinical trials have been conducted on this specific blend. Individual constituent evidence: CJC-1295 has limited human PK/PD data; ipamorelin evidence is preclinical only.
Purgo Labs offers CJC-1295 / Ipamorelin Blend with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.
